Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Shared antigen vaccine | 1 |
Top 5 Target | Count |
---|---|
5-HT1D receptor(Serotonin 1d (5-HT1d) receptor) | 1 |
Target |
Mechanism 5-HT1D receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Apr 1946 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ATPase inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jun 2021 |
Sponsor / Collaborator |
Start Date05 Mar 2021 |
Sponsor / Collaborator |
Start Date14 Sep 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Dihydroergotamine Mesylate ( 5-HT1D receptor ) | Migraine With Aura More | Phase 3 |
ISA-101 | Vulvar Neoplasms More | Phase 2 |
Anti-IGF monoclonal antibodies (Shin Nippon) ( IGF-1 x IGF-2 ) | Neoplasms More | Pending |
SPI-447 ( ATPase ) | Stomach Ulcer More | Pending |